Review Article | Published:

Current pharmacotherapy for obesity

Nature Reviews Endocrinology volume 14, pages 1224 (2018) | Download Citation

Abstract

More than one-third of adults in the USA have obesity, which causes, exacerbates or adversely impacts numerous medical comorbidities, including diabetes mellitus and cardiovascular disease. Despite intensive lifestyle modifications, the disease severity warrants further aggressive intervention, including pharmacotherapy, medical devices and bariatric surgery. Noninvasive anti-obesity drugs have thus now resurfaced as targeted adjunctive therapeutic approaches to intensive lifestyle intervention, bridging the gap between lifestyle and bariatric surgery. In this Review, we discuss FDA-approved anti-obesity drugs in terms of safety and efficacy. As most of these drugs have a mean percentage weight loss reported in clinical trials but individual variations in response rates, a future direction of obesity pharmacotherapy research might include the potential for personalized medicine to target early responders to these anti-obesity drugs.

Key points

  • Obesity is a chronic, debilitating disease with devastating overall health effects and a global burden of disease; weight loss can improve these outcomes

  • Anti-obesity drugs should be initiated promptly when appropriate criteria are met if a patient fails self-directed or professionally directed lifestyle treatment

  • Anti-obesity drugs are approved in patients with a BMI ≥27 kg/m2 with at least one obesity-related comorbidity such as diabetes mellitus, hypertension, hyperlipidaemia or sleep apnoea or in patients with a BMI ≥30 kg/m2

  • Currently, six major FDA-approved anti-obesity medications are available: phentermine, orlistat, phentermine/topiramate extended release (ER), lorcaserin, naltrexone sustained release (SR)/bupropion SR and liraglutide (the only injectable formulation)

  • Most of these anti-obesity drugs have an efficacy of 3–7% (estimated net weight loss)

  • Identifying the type of obesity on clinical presentation coupled with an understanding of anti-obesity drug safety, contraindications and adverse effect profiles can selectively increase weight loss through appropriate use of these drugs

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , & Economic burden of obesity: a systematic literature review. Int. J. Environ. Res. Public Health 14, E435 (2017).

  2. 2.

    GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med. 377, 13–27 (2017).

  3. 3.

    , , , & Trends in obesity among adults in the United States, 2005 to 2014. JAMA 315, 2284–2291 (2016).

  4. 4.

    , , & Appetite control and energy balance regulation in the modern world: reward-driven brain overrides repletion signals. Int. J. Obes. 33 (Suppl. 2), S8–S13 (2009).

  5. 5.

    & Central and peripheral regulation of food intake and physical activity: pathways and genes. Obesity (Silver Spring) 16 (Suppl. 3), S11–S22 (2008).

  6. 6.

    Interactions between the “cognitive” and “metabolic” brain in the control of food intake. Physiol. Behav. 91, 486–498 (2007).

  7. 7.

    , , & Behavioral and pharmacologic therapies for obesity. Nat. Rev. Endocrinol. 6, 578–588 (2010).

  8. 8.

    et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 100, 342–362 (2015).

  9. 9.

    , , , & The role of gut hormones and the hypothalamus in appetite regulation. Endocr. J. 57, 359–372 (2010).

  10. 10.

    et al. Gut–brain cross-talk in metabolic control. Cell 168, 758–774 (2017).

  11. 11.

    & Unraveling the brain regulation of appetite: lessons from genetics. Nat. Neurosci. 15, 1343–1349 (2012).

  12. 12.

    , , , & Revisiting the adipocyte: a model for integration of cytokine signaling in the regulation of energy metabolism. Am. J. Physiol. Endocrinol. Metab. 309, E691–E714 (2015).

  13. 13.

    , & Brown and beige fat: the metabolic function, induction, and therapeutic potential. Front. Med. 9, 162–172 (2015).

  14. 14.

    , , , & Traveling from the hypothalamus to the adipose tissue: the thermogenic pathway. Redox Biol. 12, 854–863 (2017).

  15. 15.

    & Obesity and the microbiome. Exp. Rev. Gastroenterol. Hepatol. 9, 1087–1099 (2015).

  16. 16.

    Obesity and the gut microbiome: pathophysiological aspects. Horm. Mol. Biol. Clin. Investig. 17, 53–61 (2014).

  17. 17.

    , , & Sudden death associated with thyroid hormone abuse. Am. J. Med. 71, 887–890 (1981).

  18. 18.

    , , & 2,4-Dinitrophenol (DNP): a weight loss agent with significant acute toxicity and risk of death. J. Med. Toxicol. 7, 205–212 (2011).

  19. 19.

    et al. Increasing frequency of severe clinical toxicity after use of 2,4-dinitrophenol in the UK: a report from the National Poisons Information Service. Emerg. Med. J. 32, 383–386 (2015).

  20. 20.

    & The cataractogenic activity of 2,4-dinitrophenol in ducks and rabbits. Toxicol. Appl. Pharmacol. 14, 475–486 (1969).

  21. 21.

    Weight management in obesity — past and present. Int. J. Clin. Pract. 70, 206–217 (2016).

  22. 22.

    Medical treatment of obesity: the past, the present and the future. Best Pract. Res. Clin. Gastroenterol. 28, 665–684 (2014).

  23. 23.

    et al. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin. Pharmacol. Ther. 51, 586–594 (1992).

  24. 24.

    Long-term weight control study: conclusions. Clin. Pharmacol. Ther. 51, 642–646 (1992).

  25. 25.

    et al. Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. J. Pharmacol. Exp. Ther. 269, 792–798 (1994).

  26. 26.

    & Aminorex, dexfenfluramine, and primary pulmonary hypertension. J. Clin. Epidemiol. 51, 361–364 (1998).

  27. 27.

    et al. Valvular heart disease associated with fenfluramine–phentermine. N. Engl. J. Med. 337, 581–588 (1997).

  28. 28.

    & Sibutramine effects on central mechanisms regulating energy homeostasis. Curr. Neuropharmacol. 10, 49–52 (2012).

  29. 29.

    , , , & Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335, 1194–1199 (2007).

  30. 30.

    et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 363, 905–917 (2010).

  31. 31.

    et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes. Metab. 14, 523–530 (2012).

  32. 32.

    Department of Health and Human Services, Food and Drug Administration & Center for Drug Evaluation and Research (CDER). Guidance for Industry: developing products for weight management. FDA (2007).

  33. 33.

    , & Clinical Management of Obesity 1st edn (Professional Communications, 2015).

  34. 34.

    , & Use of prescription antiobesity drugs in the United States. Pharmacotherapy 33, 1299–1307 (2013).

  35. 35.

    et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int. J. Obes. 38, 292–298 (2014).

  36. 36.

    & Neurochemical mechanism of action of anorectic drugs. Pharmacol. Toxicol. 73, 63–68 (1993).

  37. 37.

    , , & Comparison of continuous and intermittent anorectic therapy in obesity. Br. Med. J. 1, 352–354 (1968).

  38. 38.

    et al. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring) 21, 2163–2171 (2013).

  39. 39.

    [No authors listed.] In brief: phentermine (Lomaira) for weight loss. Med. Lett. Drugs Ther. 58, 158 (2016).

  40. 40.

    & Long-term drug treatment for obesity: a systematic and clinical review. JAMA 311, 74–86 (2014).

  41. 41.

    , & Obesity begets atrial fibrillation: a contemporary summary. Circulation 128, 401–405 (2013).

  42. 42.

    & The 2013 American Heart Association/American College of Cardiology/The Obesity Society Guideline for the management of overweight and obesity in adults: what is new about diet, drugs, and surgery for obesity? Circulation 132, 1586–1591 (2015).

  43. 43.

    & Obesity and cardiovascular disease. Circulation 125, 1178–1182 (2012).

  44. 44.

    & Orlistat: a review of its use in the management of obesity. Drugs 58, 743–760 (1999).

  45. 45.

    , , & XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27, 155–161 (2004).

  46. 46.

    , , & The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int. J. Obes. Relat. Metabol. Disord. 25, 1713–1721 (2001).

  47. 47.

    et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch. Intern. Med. 160, 1321–1326 (2000).

  48. 48.

    et al. Orlistat and acute kidney injury: an analysis of 953 patients. Arch. Intern. Med. 171, 703–704 (2011).

  49. 49.

    Xenical (Orlistat) package insert (Genentech, 2016).

  50. 50.

    , , & Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin. Ther. 25, 1107–1122 (2003).

  51. 51.

    & Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. Handb. Exp. Pharmacol. 209, 433–466 (2012).

  52. 52.

    et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 20, 330–342 (2012).

  53. 53.

    et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 377, 1341–1352 (2011).

  54. 54.

    et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am. J. Clin. Nutr. 95, 297–308 (2012).

  55. 55.

    Clinical briefing document: Endocrinologic and Metabolic Drugs Advisory Committee Meeting (February 22, 2012). New Drug Application 22580: VI-0521 Qnexa (phentermine/topiramate). Sponsor: Vivus. FDA (2017).

  56. 56.

    et al. Topiramate use in pregnancy and the birth prevalence of oral clefts. Pharmacoepidemiol. Drug Saf. 23, 1017–1025 (2014).

  57. 57.

    et al. Pharmacokinetic interactions of topiramate. Clin. Pharmacokinet. 43, 763–780 (2004).

  58. 58.

    Qsymia (phentermine and topiramate extended-release) package insert (Vivus, 2014).

  59. 59.

    , & Combining pharmacological and psychological treatments for binge eating disorder: current status, limitations, and future directions. Curr. Psychiatry Rep. 18, 55 (2016).

  60. 60.

    et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Surg. Obes. Relat. Dis. 13, 491–500 (2017).

  61. 61.

    Topamax (topiramate) package insert (Janssen Pharmaceuticals, 2009).

  62. 62.

    et al. Language disturbances as side effects of topiramate and zonisamide therapy. Epilepsy Behav. 2, 579–584 (2001).

  63. 63.

    Belviq (lorcaserin HCl) package insert (Arena Pharmaceuticals, 2012).

  64. 64.

    et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther. 325, 577–587 (2008).

  65. 65.

    , , , & Brain serotonin system in the coordination of food intake and body weight. Pharmacol. Biochem. Behav. 97, 84–91 (2010).

  66. 66.

    , & Serotonin, eating behavior, and fat intake. Obes. Res. 3 (Suppl. 4), 471S–476S (1995).

  67. 67.

    et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J. Clin. Endocrinol. Metab. 96, 3067–3077 (2011).

  68. 68.

    et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 363, 245–256 (2010).

  69. 69.

    et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 20, 1426–1436 (2012).

  70. 70.

    , & Opioids hyperpolarize beta-endorphin neurons via mu-receptor activation of a potassium conductance. Neuroendocrinology 52, 268–275 (1990).

  71. 71.

    et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 17, 30–39 (2009).

  72. 72.

    Naltrexone/bupropion for the treatment of obesity and obesity with type 2 diabetes. Future Cardiol. 12, 129–138 (2016).

  73. 73.

    et al. Bupropion SR versus placebo for weight loss in obese patients with depressive symptoms. Obes. Res. 10, 1049–1056 (2002).

  74. 74.

    et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376, 595–605 (2010).

  75. 75.

    et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 21, 935–943 (2013).

  76. 76.

    et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 19, 110–120 (2011).

  77. 77.

    et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 36, 4022–4029 (2013).

  78. 78.

    Contrave package insert (Takeda Pharmaceuticals, 2014).

  79. 79.

    , , , & Overview of the treatment of binge eating disorder. CNS Spectr. 20, 546–556 (2015).

  80. 80.

    & Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 74, 400–406 (2013).

  81. 81.

    & Opioid peptides and the control of human ingestive behaviour. Neurosci. Biobehav. Rev. 26, 713–728 (2002).

  82. 82.

    et al. Psychopathological behaviour and cognition in morbid obesity. Recent Pat. Endocr. Metab. Immune Drug Discov. 10, 112–118 (2016).

  83. 83.

    et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374, 1606–1616 (2009).

  84. 84.

    et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int. J. Obes. 36, 843–854 (2012).

  85. 85.

    et al. A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. N. Engl. J. Med. 373, 11–22 (2015).

  86. 86.

    et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial. JAMA 314, 687–699 (2015).

  87. 87.

    et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int. J. Obes. 37, 1443–1451 (2013).

  88. 88.

    et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389, 1399–1409 (2017).

  89. 89.

    , , & Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes — focus on pancreatitis and pancreas cancer. Exp. Opin. Drug Saf. 14, 171–180 (2015).

  90. 90.

    , , , & A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes. Metab. 16, 273–275 (2014).

  91. 91.

    Saxenda [package insert]. Liraglutide (rDNA) injection (Novo Nordisk, 2014).

  92. 92.

    Thyroid safety in patients treated with liraglutide. J. Endocrinol. Investig. 36, 140–145 (2013).

  93. 93.

    et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151, 1473–1486 (2010).

  94. 94.

    [Therapeutic gene clusters as drug action mechanisms] [Japanese]. Nihon Yakurigaku Zasshi 122 (Suppl.) 5P–7P (2003).

  95. 95.

    , , & [Pharmacometabonomics — the novel way to personalized drug therapy] [Russian]. Biomed. Khim. 63, 115–123 (2017).

  96. 96.

    et al. Genotype-based ancestral background consistently predicts efficacy and side effects across treatments in CATIE and STAR*D. PLoS ONE 8, e55239 (2013).

  97. 97.

    et al. Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia. Pharmacogenet. Genomics 25, 173–185 (2015).

  98. 98.

    , , & Pharmacogenomics of tamoxifen therapy. Clin. Chem. 55, 1770–1782 (2009).

  99. 99.

    Blue Cross Blue Shield Association, Kaiser Foundation Health Plan & Southern California Permanente Medical Group. CYP2D6 pharmacogenomics of tamoxifen treatment. Technol. Eval. Cent. Assess. Program Exec. Summ. 28, 1–4 (2014).

  100. 100.

    Pharmacogenomics toward personalized tamoxifen therapy for breast cancer. Pharmacogenomics 16, 287–296 (2015).

  101. 101.

    , , & Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab. Pharmacokinet. 27, 122–131 (2012).

  102. 102.

    , , & Minimizing weight gain for patients taking antipsychotic medications: the potential role for early use of metformin. Ann. Clin. Psychiatry 29, 120–124 (2017).

  103. 103.

    et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 299, 185–193 (2008).

  104. 104.

    et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial. JAMA Psychiatry 73, 928–937 (2016).

  105. 105.

    , , , & Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 293, 43–53 (2005).

  106. 106.

    & Advantages of percent weight loss as a method of reporting weight loss after Roux-en-Y gastric bypass. Obesity (Silver Spring) 21, 1519–1525 (2013).

Download references

Acknowledgements

The authors thank A. McCarthy for editorial and administrative assistance.

Author information

Affiliations

  1. Section of Endocrinology, Diabetes and Nutrition, Department of Medicine, Boston University School of Medicine, 720 Harrison Avenue, 8 th Floor, Suite 801, Boston, Massachusetts 02118, USA.

    • Gitanjali Srivastava
    •  & Caroline M. Apovian

Authors

  1. Search for Gitanjali Srivastava in:

  2. Search for Caroline M. Apovian in:

Contributions

G.S. and C.M.A. researched data for the article, made substantial contributions to discussions of the content, wrote the article and reviewed and/or edited the article before submission.

Competing interests

G.S. declares no competing interests. C.M.A. has received personal fees from Gelesis, GI Dynamics, Johnson and Johnson, Merck, NovoNordisk, Nutrisystem, Orexigen, Sanofi-Aventis, Scientific Intake, Takeda and Zafgen; grants from Aspire Bariatrics, the Robert C. and Veronica Atkins Foundation, Coherence Lab, Energesis, Gelesis, GI Dynamics, Myos, Orexigen, PCORI, Takeda and Vela Foundation; and other forms of support from Science-Smart. No grant support or external funding was provided to G.S. or C.M.A. for the drafting of this manuscript.

Corresponding author

Correspondence to Caroline M. Apovian.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrendo.2017.122

Further reading